Georgina Venetia Long
The University of Sydney · 1,879 works · 168,160 citations · h-index 171
Top works
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- Genomic Classification of Cutaneous Melanoma
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
- The repertoire of mutational signatures in human cancer
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma